Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02899793
Title Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer
Recruitment Active, not recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Yale University
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.